Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug ...

Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased ...

A secondary analysis of TRAILBLAZER-ALZ 2 strengthens the case that reducing amyloid plaques underlies the clinical benefits ...

Spanish and Chinese scientists say they have used nanoparticles to enable the brains of mice to clear out plaque linked to ...

A new study provides a well-needed glimmer of hope for treating Alzheimer’s disease. Focusing on a genetic form of early-onset dementia called dominantly inherited Alzheimer’s disease, scientists have ...

Clumps or plaques of the protein beta-amyloid in the brain are a hallmark of a type of dementia called Alzheimer’s disease. When beta-amyloid plaques form, they disrupt communication between nerve ...

A new study has identified a mutation in the TREM2 gene that disrupts the brain’s ability to clear toxic amyloid plaques, ...

Researchers made a significant breakthrough in Alzheimer's disease research by identifying a novel way to potentially slow down or even halt disease progression. The study, which focuses on the role ...

Kisunla will be the more expensive per-year option, with a list price of $32,000, compared to Leqembi, which is priced at $26,500 per year. With Biogen and Eisai expanding the U.S. Leqembi sales team, ...

A new scientific report reveals that the protein aggregates associated with Parkinson’s disease are not inert clumps of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission ...